SciSparc Advances Toward Clinical Trial for Tourette Treatment
SciSparc Moves Forward with Clinical Trial Application
In a significant advancement for the treatment of Tourette Syndrome, SciSparc Ltd. (NASDAQ: SPRC), a dedicated clinical-stage pharmaceutical company, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration. This application is crucial for the initiation of a Phase IIb clinical trial, aimed at evaluating the effectiveness of its proprietary drug candidate, SCI-110.
Trial Sites and Management
The upcoming clinical trial will take place at three prestigious clinical research centers: the Yale Child Study Center at the Yale School of Medicine in the United States, Hannover Medical School in Germany, and Tel Aviv Sourasky Medical Center in Israel. The approval processes have been successfully completed, with all necessary Institutional Review Board (IRB) permissions granted. Additionally, regulatory approvals from health authorities in both Israel and Germany enable the company to proceed without delay.
Aims of the Clinical Trial
During the Phase IIb trial, the main objective will be to assess the safety, efficacy, and tolerability of SCI-110 in adults diagnosed with Tourette Syndrome, aged between 18 and 65 years. Participants will be randomly assigned to receive either the drug or a placebo, adhering to a well-structured methodology designed to ensure robust results. The effectiveness of SCI-110 will be measured through the Yale Global Tic Severity Scale, an established tool in clinical settings to monitor tic severity.
Potential Impact on Patients
This study aims not only to provide insight into the drug's effectiveness but also to monitor safety parameters closely, including the occurrence of any serious adverse events among participants. Given the challenging nature of Tourette Syndrome, which severely impacts daily functioning for individuals, a successful trial could yield groundbreaking results and pave the way for improved treatment options.
Overview of SciSparc Ltd.
SciSparc Ltd. is on a mission to develop innovative therapies for the central nervous system, with a specific interest in cannabinoid-based pharmaceuticals. The company has formulated a diverse pipeline focused on addressing critical medical needs, such as SCI-110 aimed at treating Tourette Syndrome and SCI-210 designed for conditions like autism spectrum disorders and status epilepticus. Furthermore, SciSparc holds a significant stake in a subsidiary that markets hemp oil-based products through established online platforms.
Frequently Asked Questions
1. What is the primary goal of the Phase IIb clinical trial?
The primary goal is to evaluate the efficacy, safety, and tolerability of SCI-110 in treating Tourette Syndrome in adults.
2. Where will the clinical trial be conducted?
The trial will occur at esteemed institutions including Yale School of Medicine, Hannover Medical School, and Tel Aviv Sourasky Medical Center.
3. What does SCI-110 target?
SCI-110 is developed primarily for treating Tourette Syndrome, aiming to reduce tic severity.
4. How will participants be selected for the trial?
Participants aged 18 to 65 with a diagnosis of Tourette Syndrome will be randomly assigned to either the SCI-110 or placebo group.
5. What is the significance of this trial for patients?
A successful trial could lead to more effective treatment options for individuals suffering from Tourette Syndrome, improving their quality of life.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Discover the Pre-registration for Bybit's Physical Card
- Septerna Initiates Promising Clinical Trial for SEP-786
- Calian Group Partners with Microsoft for Cloud Cybersecurity Solutions
- Flow Beverage Corp. Set for Key Investor Conference Engagement
- Marqeta Sets Date for Third Quarter Financial Results Call
- UCB Reports Groundbreaking Two-Year Efficacy Data for BIMZELX
- Alpha Omega Celebrates Innovative Win in Digital Transformation
- Ovid Therapeutics' OV329 Shows Promise in Preclinical Trials
- UBS Reiterates Buy Rating for Ovintiv: Growth Prospects Ahead
- MP Materials: Strategic Growth and Optimism for Future Gains
Recent Articles
- Lincoln Financial Honors Legacy of Board Member Michael Mee
- ECD Automotive Design Welcomes New CFO and Board Chairperson
- Morningstar Announces Consistent Dividend Payout for Investors
- Kayne Anderson Energy Infrastructure Fund Secures $100 Million
- Tupperware Brands Faces Delisting from NYSE: Understanding the Process
- Steelcase Inc. Delivers Strong Growth in Q2 Fiscal 2025
- Record Rise in Foreign Holdings of U.S. Treasuries Revealed
- Market Update: Fed's Bold 50 Basis Point Rate Cut Effects
- American Healthcare REIT Announces Major Stock Offering Plans
- Ascendis Pharma's $300 Million Offering: Innovations Ahead
- KeyCorp Adjusts Prime Lending Rate to 8.00 Percent
- Douglas Dynamics Welcomes New COO Amid Executive Changes
- Celebrating NASA's Pioneering Women in Space Exploration
- Dominate the Energy Market: Dominion Energy's Financial Maneuvering
- Trinity Biotech Launches Innovative CGM Technology in India
- Innovative Johnson Controls Metasys Upgrade Enhances Efficiency
- Playtika's Strategic Acquisition of SuperPlay: A Game-Changer
- Parke Bancorp Announces Exciting Cash Dividend for Stockholders
- Caldera Launches Innovative Direct-to-Film Software for 2024
- SciSparc Advances New Treatment for Tourette Syndrome
- Bank of America Approves Preferred Stock Dividends for Q4 2024
- Jerome Powell's Bipartisan Approach to Financial Policy Reform
- Celebrating Hispanic Heritage Month with Community Support
- Recognizing Dr. Patrick M. Tamim: A Pinnacle of Excellence in Vascular Surgery
- Golden Minerals Experiences 52-Week Low Amid Financial Strain
- TriNet's Dividend Announcement Celebrates Company Success
- How Rate Cuts Can Improve Borrowing for U.S. Consumers
- Empowering Future Doctors: Dr. Robert Biter Scholarship Launches
- CFO Insights: PLAYSTUDIOS Stock Sale and Future Prospects
- Informatica's Insider Trading: Key Transactions and Insights
- OptiNose Stock Sale Signals Tax Compliance and Growth Plans
- OptiNose CEO's Stock Sale Signals Market Shifts Ahead
- Informatica Executive Share Sale Sparks Investor Interest
- Esperion Therapeutics' Executive Share Sale: Key Insights
- Cava Group Insider Sells Shares Amid Strong Company Growth
- Dayforce's Strategic Moves Enhance Position in Software Industry
- Sheldon Koenig's Share Sale Signals Changes for Esperion
- Real Good Food Company Faces Nasdaq Delisting Notification
- Exploring Intuitive Machines: Is Now the Time to Invest in LUNR?
- Abacus Life Calculator Hits 150,000 Milestone in Policy Valuations
- ECD Auto Design Welcomes New CFO and Board Changes Amid Growth
- NANOBIOTIX Achieves Critical Milestones in 2024 Financial Progress
- Cellebrite Completes Warrant Redemption and Future Plans
- Citadel Income Fund Increases Monthly Dividend Per Unit to $0.02
- Hydrofarm Holdings Group Receives Nasdaq Compliance Extension
- Great Lakes Dredge & Dock Showcases Growth Strategy at Conference
- Aecon Plans Upcoming Q3 Financial Results and Conference Call
- Exploring Remote Work Habits: Unplugged Productivity Insights
- Plug Power Partners with bp and Iberdrola for Green Hydrogen
- Ascendis Pharma Plans Major Public Offering of ADSs